MarketCapExport financials
Spero Therapeutics (SPRO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Spero Therapeutics Financial Ratios 2025-2011 | SPRO
Brief overview of Spero Therapeutics's financial ratios
The review covers five available annual periods spanning 2021 to 2025.
Key multiples at the end of the period are EV/EBITDA 16.22x (median 2.65x), P/S 1.99x (median 1.99x), P/B 2.25x (median 2.25x). The combined ratio level is close to the company's five-year norm at a 0% deviation. No clear premium or discount is visible.
Capital efficiency is characterized by ROE 14.5%, ROA 12.4%, ROCE 10.7%. Capital returns look adequate and support overall financial resilience.
Overall picture
Spero Therapeutics trades near its familiar ratio range. A new earnings or profitability trend is needed to change the view.
Annual Financial Ratios Spero Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
15.5 | -1.9 | 3.8 | -1.1 | -4.1 | -4.2 | -2.9 | -3.7 | -0.8 | - | -4.9 | - | - | - | - |
P/S |
2.0 | 2.7 | 0.8 | 1.0 | 20.1 | 35.3 | 9.7 | 38.4 | 16.2 | - | - | - | - | - | - |
EPS |
0.1 | -1.3 | 0.4 | -1.2 | -2.9 | -3.5 | -3.4 | -2.6 | -17.8 | -95.9 | -53.1 | - | - | - | - |
EV (Enterprise Value) |
102 M | 140 M | 86.7 M | -7.24 M | 337 M | 265 M | 178 M | 131 M | -46.7 M | 7.41 M | 56.9 M | - | - | - | - |
EBITDA per Share |
0.11 | -1.36 | 0.41 | -1.1 | -2.83 | -4.31 | -3.44 | -2.65 | -16 | - | -0.971 | - | - | - | - |
EV/EBITDA |
16.2 | -1.9 | 4.0 | 0.2 | -3.6 | -3.1 | -2.3 | -2.8 | 1.3 | - | -4.4 | - | - | - | - |
PEG |
-0.1 | 0.01 | -0.11 | 0.05 | - | 0.15 | 0.1 | -0.04 | 0.01 | - | 1.63 | - | - | - | - |
P/B |
2.2 | 2.8 | 0.8 | 0.7 | 4.2 | 2.5 | 2.4 | 1.3 | 0.4 | - | 252.4 | - | - | - | - |
P/CF |
-10.5 | -5.5 | -2.7 | -6.9 | -5.7 | -3.8 | -3.5 | -3.6 | -0.8 | - | -5.0 | - | - | - | - |
ROE % |
14.52 | -148.66 | 21.34 | -61.13 | -101.66 | -59.29 | -81.70 | -36.07 | -45.79 | - | -5180.61 | - | - | - | - |
ROA % |
12.44 | -62.03 | 12.50 | -37.19 | -52.47 | -51.01 | -57.42 | -32.29 | -41.45 | - | -141.50 | - | - | - | - |
ROCE % |
10.70 | -159.06 | 20.10 | -55.57 | -99.64 | -56.87 | -79.58 | -36.68 | -48.91 | - | -1742.12 | - | - | - | - |
Current Ratio |
7.0 | 1.7 | 2.4 | 2.6 | 2.1 | 9.7 | 3.6 | 10.1 | 11.3 | - | 0.9 | - | - | - | - |
DSO |
- | - | - | - | - | 241.6 | 171.9 | 119.5 | 542.8 | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Financial Ratios Spero Therapeutics
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.03 | -0.13 | - | -0.13 | -0.03 | -0.25 | - | -0.32 | -0.33 | -0.24 | - | -0.06 | -0.23 | -0.25 | - | -0.33 | -0.87 | -1.01 | - | -0.7 | -0.63 | -0.66 | - | -0.86 | -0.85 | -1.22 | -1.31 | -0.95 | -0.74 | -0.29 | -0.6 | -0.6 | -0.69 | -0.74 | -1.59 | -36.02 | -36.21 | -21.6 | -25.68 | -23.23 | -25.3 | -21.51 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.04 | -0.13 | - | - | - | - | - | - | - | - | - | - | - | -0.27 | - | -0.31 | -0.78 | -0.92 | - | -0.69 | -0.61 | -0.65 | - | -0.84 | -0.88 | -1.16 | - | -0.92 | -0.75 | -0.32 | - | -0.61 | -0.68 | -0.75 | - | -28.9 | -29.9 | -22.8 | - | -24.2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-50.33 | -87.66 | -74.05 | -100.22 | -94.55 | -102.53 | -61.53 | -67.50 | -63.04 | -61.37 | -48.20 | -84.22 | -158.15 | -188.93 | -168.41 | -188.52 | -173.11 | -109.54 | -57.04 | -71.35 | -64.50 | -61.54 | -45.21 | -78.72 | -88.14 | -92.59 | -81.78 | -57.45 | -42.77 | -33.69 | -36.07 | -43.28 | -79.96 | -117.09 | -153.62 | -121.36 | -61.72 | -45.74 | 15.87 | 13.90 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-31.03 | -46.41 | -34.21 | -46.89 | -45.18 | -50.00 | -32.16 | -35.15 | -34.50 | -34.40 | -26.84 | -44.99 | -87.10 | -97.56 | -85.74 | -101.29 | -98.70 | -67.12 | -44.63 | -56.94 | -52.80 | -52.43 | -38.90 | -62.45 | -66.82 | -67.86 | -57.48 | -42.15 | -33.57 | -28.85 | -32.29 | -38.91 | -72.20 | -105.88 | -139.03 | -176.56 | -181.02 | -41.40 | -52.36 | -45.86 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-56.86 | -95.13 | -80.89 | -109.27 | -103.07 | -110.15 | -66.59 | -70.19 | -65.34 | -63.60 | -49.07 | -85.50 | -154.50 | -179.32 | -157.38 | -177.51 | -161.63 | -105.35 | -57.00 | -71.41 | -65.27 | -62.01 | -45.68 | -69.80 | -73.70 | -67.35 | -50.06 | -59.53 | -44.05 | -35.10 | -27.46 | -39.24 | -41.79 | -42.14 | -32.78 | -15.36 | -12.02 | -8.98 | - | 17.42 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
7.0 | 9.7 | 1.7 | 2.0 | 2.1 | 1.8 | 1.7 | 1.9 | 2.2 | 2.4 | 2.4 | 2.0 | 2.2 | 2.4 | 2.5 | 2.0 | 2.3 | 1.8 | 2.1 | 4.4 | 4.1 | 5.8 | 7.2 | 7.2 | 7.2 | 7.2 | 3.4 | 3.4 | 3.4 | 3.4 | 9.8 | 9.8 | 9.8 | 9.8 | 11.0 | 11.0 | 11.0 | 11.0 | 1.9 | 1.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Multiples are an important financial analysis tool for the company Spero Therapeutics, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Britain
Germany
China
Belgium
USA
Canada
Israel
Bermuda
France
Danmark
